Aldred, Jason and Anca-Herschkovitsch, Marieta and Antonini, Angelo and Bajenaru, Ovidiu and Bergmann, Lars and Kovács, Norbert (2020) Application of the '5-2-1' screening criteria in advanced Parkinson's disease : interim analysis of DUOGLOBE. NEURODEGENERATIVE DISEASE MANAGEMENT, 10 (5). pp. 309-323. ISSN 1758-2024
|
Text
2020_nmt_521_2020_0021.pdf Download (1MB) | Preview |
Abstract
Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the '5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with 'Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD - a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) - is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. Clinical Trial Registration: NCT02611713 (ClinicalTrials.gov).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Parkinson's disease; levodopa; dyskinesia; levodopa-carbidopa intestinal gel; OFF time; LCIG; 5-2-1; criteria for advanced PD; |
| Subjects: | R Medicine / orvostudomány > RC Internal medicine / belgyógyászat > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry / idegkórtan, neurológia, pszichiátria |
| SWORD Depositor: | MTMT SWORD |
| Depositing User: | MTMT SWORD |
| Date Deposited: | 04 Jan 2021 15:01 |
| Last Modified: | 04 Jan 2021 15:01 |
| URI: | http://real.mtak.hu/id/eprint/119053 |
Actions (login required)
 |
Edit Item |
